SFX-01

DRUG2 trials

Sponsors

Evgen Pharma

Conditions

Breast NeoplasmSubarachnoid Hemorrhage, Spontaneous

Phase 2

SFX-01 After Subarachnoid Haemorrhage

CompletedNCT02614742

Evgen PharmaSubarachnoid Hemorrhage, Spontaneous

Start: 2016-04-30End: 2019-11-30Updated: 2020-01-18

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

CompletedNCT02970682

Evgen PharmaBreast Neoplasm

Start: 2016-10-31End: 2019-03-31Target: 60Updated: 2019-07-12

Related Papers

A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study

Translational Stroke Research2024-07-196 citations

Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial

BMJ Open2020-03-0133 citations